What Is Dulaglutide?

1. What the Molecule Is

Native GLP-1 lasts minutes in the blood before an enzyme, DPP-4, cuts it apart. Every GLP-1 drug is a way of getting around that. Liraglutide and semaglutide do it with a fatty-acid chain that binds albumin. Dulaglutide does it differently: the GLP-1 analogue sequence, 90% identical to human GLP-1, is attached by a short linker to the Fc portion of a modified human IgG4 antibody. Two of these chains are disulfide-linked, so the finished molecule is a large fusion protein made in Chinese hamster ovary cells, not a synthetic peptide.

The Fc fragment does two things. It makes the molecule too large for the kidney to filter, and it is recycled by the same receptor that keeps antibodies circulating for weeks. The label reports an elimination half-life of about 5 days and steady state after 2 to 4 weeks of weekly injections. Lilly’s own engineering paper describes the design goal plainly: extended pharmacokinetics from a GLP-1 immunoglobulin G4 Fc fusion.

Once at the receptor, it does what the class does: glucose-dependent insulin release, suppressed glucagon, slower gastric emptying, and reduced appetite.

2. The Outcomes Evidence: REWIND

REWIND is the trial that matters most. It is the only dulaglutide outcomes trial, and it was unusual for the class because most participants had cardiovascular risk factors rather than established cardiovascular disease.

All-cause death was 10.8% versus 12.0%, hazard ratio 0.90, which did not reach significance. Gastrointestinal adverse events were reported by 47.4% on dulaglutide versus 34.1% on placebo. REWIND earned Trulicity its indication for reducing major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors, and it is why dulaglutide was chosen as the active comparator when Lilly ran tirzepatide’s outcomes trial.

3. The AWARD Program

AWARD is Lilly’s phase 3 series for dulaglutide. The results that still shape the label:

AWARD-6 is the historically important one: it showed a weekly injection could match the best daily GLP-1 drug of the time. AWARD-11 is the reason the dose ceiling rose from 1.5 mg to 4.5 mg. AWARD-PEDS is the basis of the pediatric indication.

4. Head-to-Head Against Newer Molecules

Dulaglutide has been the comparator in two trials that defined the next generation.

Semaglutide, SUSTAIN 7. 1,201 adults with type 2 diabetes, 40 weeks. Semaglutide 1 mg lowered HbA1c by 1.8 points versus 1.4 for dulaglutide 1.5 mg, and weight by 6.5 kg versus 3.0 kg. At the lower doses, semaglutide 0.5 mg versus dulaglutide 0.75 mg, the pattern was the same: 4.6 kg versus 2.3 kg. Gastrointestinal events ran 43% to 44% on semaglutide against 33% on dulaglutide 0.75 mg and 48% on dulaglutide 1.5 mg, so the two top doses were similar on tolerability.

Tirzepatide, SURPASS-CVOT. 13,299 adults with type 2 diabetes and cardiovascular disease. Tirzepatide was tested against dulaglutide rather than placebo, precisely because REWIND had shown dulaglutide reduces events. Major adverse cardiovascular events occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide, hazard ratio 0.92, meeting non-inferiority but not superiority. That trial gave Mounjaro a cardiovascular indication in 2026, and it also means dulaglutide is the benchmark the newer drug was measured against.

Neither comparison used dulaglutide’s higher 3 mg or 4.5 mg doses, which were approved after SUSTAIN 7 was designed. An indirect comparison suggests semaglutide 2 mg still produces more weight loss than dulaglutide 4.5 mg, but no head-to-head trial has tested it.

5. Where It Sits Now

Dulaglutide’s place is a well-tolerated weekly diabetes drug with a long cardiovascular record and a modest weight effect. It was never developed for obesity, and the AWARD-11 numbers, 3 to 4.6 kg, show why. For device, storage, missed-dose rules, and the label’s safety sections, see the Trulicity page.

6. Tracking Note

Dulaglutide is logged like any weekly injectable: product, date, milligrams, injection site. Its 5-day half-life means a dose is largely gone about 3 to 4 weeks after the last injection, which the half-life visualizer can plot. How GLP-1 tracking works covers what to record.

7. What Is Dulaglutide FAQ

• What is dulaglutide in simple terms?

  A once-weekly injectable drug for type 2 diabetes that mimics the gut hormone GLP-1. It is two GLP-1-like peptide chains attached to an antibody fragment, which keeps it in the body for about five days per dose. Its only brand is Trulicity.

• Is dulaglutide the same as Trulicity?

  Dulaglutide is the molecule; Trulicity is Lilly's brand and the only product that contains it. There is no generic dulaglutide.

• Does dulaglutide reduce heart attacks and strokes?

  In REWIND, the composite of cardiovascular death, heart attack, and stroke occurred in 12.0% of people on dulaglutide versus 13.4% on placebo over a median 5.4 years, a hazard ratio of 0.88. That result is the basis of Trulicity's cardiovascular indication. All-cause death was not significantly different.

• How does dulaglutide compare with semaglutide and tirzepatide?

  Both beat it head-to-head. In SUSTAIN 7, semaglutide 1 mg lowered HbA1c by 1.8 points versus 1.4 for dulaglutide 1.5 mg, with 6.5 kg versus 3.0 kg weight loss. In SURPASS-CVOT, tirzepatide was non-inferior to dulaglutide on major cardiovascular events, 12.2% versus 13.1%, hazard ratio 0.92. Dulaglutide's own dose range was later extended to 4.5 mg, which narrows but does not close the gap.

• Is dulaglutide used for weight loss?

  No. It has no weight-management indication and its weight effect in trials is small: about 3 kg at the 1.5 mg dose over 36 weeks in AWARD-11, and 4.6 kg at 4.5 mg. Semaglutide and tirzepatide produce several times that.

8. Sources